Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO
Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO
此前报道，Medicinova 宣布了有关胶质母细胞瘤 MN-166 临床试验结果的摘要，该结果获准在 2024 年 ASCO 上发表
Abstract Number: 2106
摘要编号：2106
Title: Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM)
标题：1b/2a 期研究评估 MN-166（伊布地拉特）和替莫唑胺联合治疗新诊断和复发性胶质母细胞瘤（GBM）患者的情况
Session Title: Rapid Oral Abstract – Central Nervous System Tumors
Session Date: June 2, 2024
Session Time: 11:30 AM – 1:00 PM
会议标题：快速口头摘要——中枢神经系统肿瘤
会议日期：2024 年 6 月 2 日
会议时间：上午 11:30 — 下午 1:00